GTIS Partners Closes $680 Million Brazil Real Estate Fund III
GTIS Partners LP (“GTIS”), a real estate private equity firm headquartered in New York City, with offices in São Paulo, Los Angeles, San Francisco, Atlanta, Paris, and Munich, held its final closing for the GTIS Brazil Real Estate Fund III (“Fund III”) on December 30, 2016. A total of approximately $680,000,000 was raised largely from several institutional investors.
“We’re excited that we were able to close another fund in Brazil, and that there was robust interest among both our existing and new investors for this product,” said Josh Pristaw, Senior Managing Director at GTIS who led the fundraising effort and co-runs the Brazil business. “With the right execution capabilities, Brazil represents an attractive opportunity for real estate investing. We look forward to deploying our investment capital as new opportunities are uncovered.”
GTIS Partners has a legacy raising large funds for its Brazil investment activities. The firm previously raised $810.2 million for GTIS Brazil Real Estate Fund II in December 2011, and approximately $510 million between 2008‐2009 during the first round of funding as well as approximately $700 million of capital in co-investment vehicles. To date, GTIS has committed approximately $2.1 billion to investments in Brazil, making it one of the most active real estate managers there.
“We’re proud to say that Fund III is one of the only Latin American real estate funds to have closed this year,” noted Tom Shapiro, President and Founder of GTIS. “We currently have approximately 2 million square meters either built or under development including over 700,000 square meters of office and industrial/logistics assets, and over 14,000 residential units and approximately 10,000 hotel keys across São Paulo and Rio, and look forward to building out that portfolio with the proceeds of this new fund.”
“Our combination of a vertically integrated best-in-class local platform with a US-based institutional infrastructure is a unique differentiator as we source and execute on transactions,” noted Joao Teixeira, Senior Managing Director and Co-head of Brazil for GTIS.
About GTIS Partners
GTIS Partners is a global real estate investment firm headquartered in New York with offices in Los Angeles, San Francisco, Atlanta, São Paulo, Brazil, Paris, France and Munich, Germany. GTIS Partners was founded in 2005 and is managed by President Tom Shapiro and Senior Managing Directors Josh Pristaw, Rob Vahradian, Tom Feldstein and Joao Teixeira. GTIS Partners has 83 employees and currently has approximately $3.6 billion of assets under management. The firm pursues opportunistic real estate investments through direct equity investment and non-traditional lending activities. To date, the firm has committed capital to residential, retail, industrial, office, hotel and mixed-use projects in the U.S. and Brazil, and is among the largest real estate private equity companies in Brazil. For more information, please visit www.gtispartners.com.
Water & Wall Group
Gina Feghali, 212-625-2365
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses20.11.2017 00:01 | Pressemelding
Shell and bio-bean announce that together they are helping to power some of London’s buses using a biofuel made partly from waste coffee grounds. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005060/en/ Shell and bio-bean announce that together they are helping to power some of London's buses using a biofuel made partly from waste coffee grounds (Photo: Business Wire) The B20 biofuel contains a 20% bio-component which contains part coffee oil. The biofuel is being added to the London bus fuel supply chain and will help to power some of the buses; without need for modification. Biofuel provides a cleaner, more sustainable energy solution for buses across London’s network by decreasing emissions1. “Our Coffee Logs have already become the fuel of choice for households looking for a
Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®19.11.2017 22:21 | Pressemelding
Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT ® , a biosimilar referencing Herceptin ® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT ® is the first trastuzumab biosimilar to receive regulatory approval in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) The EC approval of ONTRUZANT ® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT ® will be commercial
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom